NCT03028337

Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases

Active, enrolled Phase 2 Last updated 5 March 2026

What this trial tests

Phase 2 trial testing Spine Radiosurgery in Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 January 2017

Primary endpoint
30 May 2028

30 May 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	80
Start date	18 January 2017
Primary completion	30 May 2028
Estimated completion	30 May 2028
Sites	1 location across United States

Drugs / interventions tested

• Spine Radiosurgery
• Questionnaires

Conditions studied

• Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System — all drugs for Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn whether delivering spine radiosurgery in a single large dose is better than delivering spine radiosurgery over 3 smaller doses.

Researchers also want to learn about the effects of a single dose on participant's symptoms, pain, and quality-of-life.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current and Emerging Approaches for Spine Tumor Treatment.
   Costăchescu B, Niculescu AG, Iliescu BF, Dabija MG, et al · · 2022 · cited 17× · PMID 36555324 · DOI 10.3390/ijms232415680
2. Management of recurrent or progressive spinal metastases: reirradiation techniques and surgical principles.
   Kotecha R, Dea N, Detsky JS, Sahgal A. · · 2020 · cited 16× · PMID 33299573 · DOI 10.1093/nop/npaa045
3. Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives.
   Loi M, Nuyttens JJ, Desideri I, Greto D, et al · · 2019 · cited 10× · PMID 31807069 · DOI 10.2147/cmar.s186630
4. Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery.
   Sherry AD, Maroongroge S, De B, Amini B, et al · · 2023 · cited 4× · PMID 37667065 · DOI 10.1007/s11060-023-04432-1
5. Is single fraction the future of stereotactic body radiation therapy (SBRT)? A critical appraisal of the current literature.
   Terlizzi M, Limkin E, Sellami N, Louvel G, et al · · 2023 · cited 4× · PMID 36816840 · DOI 10.1016/j.ctro.2023.100584
6. Preventive strategies against brain metastases: current state of the art and future directions.
   Ippen FM, Konen FF, Hau P, Winkler F. · · 2026 · PMID 41928334 · DOI 10.1186/s42466-026-00467-7